- Mineralys Therapeutics, Inc. recently reported that its 2025 fourth-quarter net loss narrowed to US$32.23 million from US$48.95 million a year earlier, while the U.S. FDA accepted its New Drug Application for lorundrostat in adult hypertension with a PDUFA action date of December 22, 2026.
- The combination of reduced annual net loss to US$154.65 million and FDA review acceptance for lorundrostat marks a shift toward a more advanced, late-stage profile for Mineralys as it moves closer to a potential commercial decision point in hypertension.
- We’ll now examine how the FDA’s acceptance of lorundrostat’s hypertension NDA may reshape Mineralys Therapeutics’ investment narrative and outlook.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Mineralys Therapeutics Investment Narrative Recap
To own Mineralys Therapeutics today, you need to believe lorundrostat can clear the U.S. FDA review and become a meaningful option in difficult‑to‑treat hypertension, while the company manages cash burn on the way to a commercial decision. The FDA’s acceptance of the hypertension NDA and a December 22, 2026 PDUFA date sharpens that regulatory catalyst, but also concentrates risk around a single binary event, with ongoing net losses remaining a key concern in the near term.
The most relevant recent development is the FDA’s acceptance of Mineralys’ NDA for lorundrostat in adult hypertension, supported by five positive Phase 2/3 trials and a favorable safety profile. Coupled with a narrower 2025 net loss of US$154.65 million, this positions Mineralys as a later‑stage biotech with a defined regulatory timeline, but it does not remove the risks tied to continued cash usage and the outcome of that PDUFA decision.
However, investors should also weigh how reliance on a single asset and persistent net losses could pressure the business if the PDUFA outcome or launch timing disappoints...
Read the full narrative on Mineralys Therapeutics (it's free!)
Mineralys Therapeutics’ narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This requires earnings to increase by about $195 million from -$171.4 million today.
Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 111% upside to its current price.
Exploring Other Perspectives
Before this NDA news, the most optimistic analysts were modeling about US$387.9 million of revenue and roughly US$48.5 million of earnings by 2029, which is far more bullish than consensus and assumes lorundrostat clears key risks like the PDUFA decision and competing launches; your own view on those uncertainties may lead you to a very different conclusion.
Explore 5 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $41.36!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Mineralys Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.
Interested In Other Possibilities?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
- Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com